AZD-3783 is a serotonin 5-HT<sub>1B</sub> receptor antagonist which was under development for the treatment of major depressive disorder and anxiety disorders. It was being developed by AstraZeneca. The drug reached phase 1 clinical trials prior to the discontinuation of its development. It was discontinued following unexpected neurotoxicity findings in animals.